New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes

Classical hairy cell leukemia (HCL-c) is a rare lymphoid neoplasm. BRAFV600E mutation, detected in more than 80% of the cases, is described as a driver mutation, but additional genetic abnormalities appear to be necessary for the disease progression. For cases of HCL-c harboring a wild-type BRAF gene, the differential diagnosis of the variant form of HCL (HCL-v) or splenic diffuse red pulp lymphoma (SDRPL) is complex. We selected a panel of 21 relevant genes based on a literature review of whole exome sequencing studies (BRAF, MAP2K1, DUSP2, MAPK15, ARID1A, ARID1B, EZH2, KDM6A, CREBBP, TP53, CDKN1B, XPO1, KLF2, CXCR4, NOTH1, NOTCH2, MYD88, ANXA1, U2AF1, BCOR, and ABCA8). We analyzed 20 HCL-c and 4 HCL-v patients. The analysis of diagnostic samples mutations in BRAF (n = 18), KLF2 (n = 4), MAP2K1 (n = 3), KDM6A (n = 2), CDKN1B (n = 2), ARID1A (n = 2), CREBBP (n = 2) NOTCH1 (n = 1) and ARID1B (n = 1). BRAFV600E was found in 90% (18/20) of HCL-c patients. In HCL-c patients with BRAFV600E, other mutations were found in 33% (6/18) of cases. All 4 HCL-v patients had mutations in epigenetic regulatory genes: KDM6A (n = 2), CREBBP (n = 1) or ARID1A (n = 1). The analysis of sequential samples (at diagnosis and relapse) from 5 patients (2 HCL-c and 3 HCL-v), showed the presence of 2 new subclonal mutations (BCORE1430X and XPO1E571K) in one patient and variations of the mutated allele frequency in 2 other cases. In the HCL-v disease, we described new mutations targeting KDM6A that encode a lysine demethylase protein. This opens new perspectives for personalized medicine for this group of patients.

[1]  James M. Bogenberger,et al.  Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. , 2017, Blood.

[2]  G. Salles,et al.  Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies , 2017, Leukemia & lymphoma.

[3]  Swe Swe Myint,et al.  Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2 , 2017, Science Translational Medicine.

[4]  F. Jardin,et al.  XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy , 2017, Journal of Hematology & Oncology.

[5]  Jeffrey A Jones,et al.  Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. , 2017, Blood.

[6]  Andrew J. Dunford,et al.  Tumor suppressor genes that escape from X-inactivation contribute to cancer sex bias , 2016, Nature Genetics.

[7]  J. Cerhan,et al.  2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.

[8]  F. Jardin,et al.  Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma , 2016, Haematologica.

[9]  C. Copie-Bergman,et al.  Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B‐cell lymphoma , 2016, American journal of hematology.

[10]  C. Copie-Bergman,et al.  Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study , 2016, Clinical Cancer Research.

[11]  E. Campo,et al.  Hairy cell leukaemia-variant: Disease features and treatment. , 2015, Best practice & research. Clinical haematology.

[12]  O. Abdel-Wahab,et al.  BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. , 2015, Cancer cell.

[13]  C. Buske,et al.  Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  C. von Kalle,et al.  Recurrent CDKN1B (p27) mutations in hairy cell leukemia. , 2015, Blood.

[15]  M. Chiariello,et al.  MAPK15 mediates BCR-ABL1-induced autophagy and regulates oncogene-dependent cell proliferation and tumor formation , 2015, Autophagy.

[16]  Joobae Park,et al.  Overexpression of MAPK15 in gastric cancer is associated with copy number gain and contributes to the stability of c-Jun , 2015, Oncotarget.

[17]  J. Martinez-Climent,et al.  KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype , 2014, Leukemia.

[18]  S. Pileri,et al.  The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma , 2014, Leukemia.

[19]  Tatiana Popova,et al.  Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data , 2014, Bioinform..

[20]  M. Berger,et al.  Hematopoietic Stem Cell Origin of BRAFV600E Mutations in Hairy Cell Leukemia , 2014, Science Translational Medicine.

[21]  A. Rosenwald,et al.  Alternative BRAF mutations in BRAF V600E‐negative hairy cell leukaemias , 2014, British journal of haematology.

[22]  Fang Fang,et al.  The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. , 2014, Blood.

[23]  Paul S. Meltzer,et al.  High prevalence of MAP2K1 mutations in variant and IGHV4-34 expressing hairy-cell leukemia , 2013, Nature Genetics.

[24]  H. Döhner,et al.  BRAF mutations in chronic lymphocytic leukemia , 2013, Leukemia & lymphoma.

[25]  Y. Takami,et al.  Kruppel-like factor 2 is a transcriptional regulator of chronic and acute inflammation. , 2013, The American journal of pathology.

[26]  Jenny Taylor,et al.  Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. , 2012, Blood.

[27]  T. Kalina,et al.  EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols , 2012, Leukemia.

[28]  D. Catovsky,et al.  The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma , 2012, British journal of haematology.

[29]  N. Duesbery,et al.  MEK genomics in development and disease , 2012, Briefings in functional genomics.

[30]  B. Falini,et al.  Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia. , 2012, Blood.

[31]  M. Raffeld,et al.  Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. , 2012, Blood.

[32]  T. Haferlach,et al.  Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. , 2011, Blood.

[33]  S. Yokoyama,et al.  Structural basis for histone H3 Lys 27 demethylation by UTX/KDM6A. , 2011, Genes & development.

[34]  Dominique Vaur,et al.  Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes , 2011, European Journal of Human Genetics.

[35]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[36]  R. Kreitman,et al.  Molecular variant of hairy cell leukemia with poor prognosis , 2011, Leukemia & lymphoma.

[37]  G. Salles,et al.  Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B‐cell lymphoma (SRPL) , 2011, Hematological oncology.

[38]  H. Jäck,et al.  B cell homeostasis and plasma cell homing controlled by Krüppel-like factor 2 , 2010, Proceedings of the National Academy of Sciences.

[39]  S. Jameson,et al.  Krüppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression , 2010, Proceedings of the National Academy of Sciences.

[40]  W. Sellers,et al.  MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.

[41]  S. Pileri,et al.  Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. , 2009, Blood.

[42]  G. Neri,et al.  Faculty Opinions recommendation of Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. , 2009 .

[43]  Li Ding,et al.  Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. , 2008, Cancer research.

[44]  G. Salles,et al.  Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? , 2008, Blood.

[45]  N. Shinton WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[46]  M. Acunzo,et al.  Activation of the Erk8 Mitogen-activated Protein (MAP) Kinase by RET/PTC3, a Constitutively Active Form of the RET Proto-oncogene* , 2006, Journal of Biological Chemistry.

[47]  S. Perkins,et al.  Analysis of CD10+ hairy cell leukemia. , 2003, American journal of clinical pathology.

[48]  A. Kohlmann,et al.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients , 2014, Leukemia.

[49]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[50]  C. Day,et al.  P53 mutations in hairy cell leukemia , 2000, Leukemia.

[51]  D. Catovsky,et al.  The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. , 1994, Leukemia & lymphoma.